GILD - Gilead Sciences Inc. (GILD) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)
2024-06-12 21:00:07 ET
Gilead Sciences, Inc. (GILD)
Goldman Sachs 45th Annual Global Healthcare Conference
June 12, 2024 01:20 PM ET
Company Participants
Daniel O'Day - Chairman and Chief Executive Officer
Conference Call Participants
Salveen Richter - Goldman Sachs
Presentation
Salveen Richter
Good afternoon, everyone. Thank you so much for joining. We're really pleased to have the Gilead team who has joined us virtually, unfortunately, due to the weather. It was hard to make it here in person. With us, we have Dan O'Day, Chairman and CEO, and Johanna Mercier, who is the Chief Commercial Officer. Thank you so much for joining us.
Daniel O'Day
Thank you for having us, Salveen. Sorry to [Multiple Speakers]
Question-and-Answer Session
Q - Salveen Richter
So to start here, Dan, can you give us an overview of where the business stands today, including your core Infectious Disease and Oncology franchises, key priorities, and how you're thinking about the forward strategy for the company?
Daniel O’Day
Yeah, thank you, Salveen, and delighted to have the chance to communicate with all of you along with Johanna. Look, I think we are definitely making continued progress on our transformation journey that we started about five years ago. It's an arc of many years, and even as we navigate some of the recent Trodelvy Phase 3 readouts that I know we'll speak about in lung cancer and bladder cancer, we are making steady progress relative to sustainable and diversify our business over time. I mean, I would just point to the most recent quarterly call where our commercial front is very strong and our Virology business continues to be our cornerstone....
Gilead Sciences, Inc. (GILD) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)